Literature DB >> 25480913

Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis.

Miriam J Smith1, Bertand Isidor1, Christian Beetz1, Simon G Williams1, Sanjeev S Bhaskar1, Wilfrid Richer1, James O'Sullivan1, Beverly Anderson1, Sarah B Daly1, Jill E Urquhart1, Alan Fryer1, Cecilie F Rustad1, Samantha J Mills1, Amir Samii1, Daniel du Plessis1, Dorothy Halliday1, Sebastien Barbarot1, Franck Bourdeaut1, William G Newman2, D Gareth Evans2.   

Abstract

OBJECTIVES: We aimed to determine the proportion of individuals in our schwannomatosis cohort whose disease is associated with an LZTR1 mutation.
METHODS: We used exome sequencing, Sanger sequencing, and copy number analysis to screen 65 unrelated individuals with schwannomatosis who were negative for a germline NF2 or SMARCB1 mutation. We also screened samples from 39 patients with a unilateral vestibular schwannoma (UVS), plus at least one other schwannoma, but who did not have an identifiable germline or mosaic NF2 mutation.
RESULTS: We identified germline LZTR1 mutations in 6 of 16 patients (37.5%) with schwannomatosis who had at least one affected relative, 11 of 49 (22%) sporadic patients, and 2 of 39 patients with UVS in our cohort. Three germline mutation-positive patients in total had developed a UVS. Mosaicism was excluded in 3 patients without germline mutation in NF2, SMARCB1, or LZTR1 by mutation screening in 2 tumors from each.
CONCLUSIONS: Our data confirm the relationship between mutations in LZTR1 and schwannomatosis. They indicate that germline mutations in LZTR1 confer an increased risk of vestibular schwannoma, providing further overlap with NF2, and that further causative genes for schwannomatosis remain to be identified.
© 2014 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25480913      PMCID: PMC4336087          DOI: 10.1212/WNL.0000000000001129

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  21 in total

Review 1.  Diagnostic criteria for schwannomatosis.

Authors:  M MacCollin; E A Chiocca; D G Evans; J M Friedman; R Horvitz; D Jaramillo; M Lev; V F Mautner; M Niimura; S R Plotkin; C N Sang; A Stemmer-Rachamimov; E S Roach
Journal:  Neurology       Date:  2005-06-14       Impact factor: 9.910

2.  Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis.

Authors:  Miriam J Smith; Anjana Kulkarni; Cecilie Rustad; Naomi L Bowers; Andrew J Wallace; Susan E Holder; Arvid Heiberg; Richard T Ramsden; D Gareth Evans
Journal:  Am J Med Genet A       Date:  2011-11-21       Impact factor: 2.802

3.  Paediatric presentation of type 2 neurofibromatosis.

Authors:  D G Evans; J M Birch; R T Ramsden
Journal:  Arch Dis Child       Date:  1999-12       Impact factor: 3.791

4.  Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas.

Authors:  Arkadiusz Piotrowski; Jing Xie; Ying F Liu; Andrzej B Poplawski; Alicia R Gomes; Piotr Madanecki; Chuanhua Fu; Michael R Crowley; David K Crossman; Linlea Armstrong; Dusica Babovic-Vuksanovic; Amanda Bergner; Jaishri O Blakeley; Andrea L Blumenthal; Molly S Daniels; Howard Feit; Kathy Gardner; Stephanie Hurst; Christine Kobelka; Chung Lee; Rebecca Nagy; Katherine A Rauen; John M Slopis; Pim Suwannarat; Judith A Westman; Andrea Zanko; Bruce R Korf; Ludwine M Messiaen
Journal:  Nat Genet       Date:  2013-12-22       Impact factor: 38.330

5.  Premature termination of SMARCB1 translation may be followed by reinitiation in schwannomatosis-associated schwannomas, but results in absence of SMARCB1 expression in rhabdoid tumors.

Authors:  Theo J M Hulsebos; Susan Kenter; Wim I M Verhagen; Frank Baas; Uta Flucke; Pieter Wesseling
Journal:  Acta Neuropathol       Date:  2014-04-17       Impact factor: 17.088

6.  Multiple unilateral schwannomas: segmental neurofibromatosis type 2 or schwannomatosis?

Authors:  M Leverkus; L Kluwe; E-M Röll; G Becker; E-B Bröcker; V F Mautner; H Hamm
Journal:  Br J Dermatol       Date:  2003-04       Impact factor: 9.302

7.  A clinical study of type 2 neurofibromatosis.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; V Newton; R Harris
Journal:  Q J Med       Date:  1992-08

8.  Familial schwannomatosis: exclusion of the NF2 locus as the germline event.

Authors:  M MacCollin; C Willett; B Heinrich; L B Jacoby; J S Acierno; A Perry; D N Louis
Journal:  Neurology       Date:  2003-06-24       Impact factor: 9.910

9.  Expression of SMARCB1 (INI1) mutations in familial schwannomatosis.

Authors:  Miriam J Smith; James A Walker; Yiping Shen; Anat Stemmer-Rachamimov; James F Gusella; Scott R Plotkin
Journal:  Hum Mol Genet       Date:  2012-09-04       Impact factor: 6.150

10.  The integrated landscape of driver genomic alterations in glioblastoma.

Authors:  Veronique Frattini; Vladimir Trifonov; Joseph Minhow Chan; Angelica Castano; Marie Lia; Francesco Abate; Stephen T Keir; Alan X Ji; Pietro Zoppoli; Francesco Niola; Carla Danussi; Igor Dolgalev; Paola Porrati; Serena Pellegatta; Adriana Heguy; Gaurav Gupta; David J Pisapia; Peter Canoll; Jeffrey N Bruce; Roger E McLendon; Hai Yan; Ken Aldape; Gaetano Finocchiaro; Tom Mikkelsen; Gilbert G Privé; Darell D Bigner; Anna Lasorella; Raul Rabadan; Antonio Iavarone
Journal:  Nat Genet       Date:  2013-08-05       Impact factor: 38.330

View more
  28 in total

1.  Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.

Authors:  Camille Louvrier; Eric Pasmant; Audrey Briand-Suleau; Joëlle Cohen; Patrick Nitschké; Juliette Nectoux; Lucie Orhant; Cécile Zordan; Cyril Goizet; Stéphane Goutagny; Dominique Lallemand; Michel Vidaud; Dominique Vidaud; Michel Kalamarides; Béatrice Parfait
Journal:  Neuro Oncol       Date:  2018-06-18       Impact factor: 12.300

2.  A mosaic pattern of INI1/SMARCB1 protein expression distinguishes Schwannomatosis and NF2-associated peripheral schwannomas from solitary peripheral schwannomas and NF2-associated vestibular schwannomas.

Authors:  Rosario Caltabiano; Gaetano Magro; Agata Polizzi; Andrea Domenico Praticò; Andrea Ortensi; Valerio D'Orazi; Andrea Panunzi; Pietro Milone; Luigi Maiolino; Francesco Nicita; Gabriele Lorenzo Capone; Roberta Sestini; Irene Paganini; Mariella Muglia; Sebastiano Cavallaro; Salvatore Lanzafame; Laura Papi; Martino Ruggieri
Journal:  Childs Nerv Syst       Date:  2017-04-01       Impact factor: 1.475

Review 3.  Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.

Authors:  Jaishri O Blakeley; Scott R Plotkin
Journal:  Neuro Oncol       Date:  2016-02-06       Impact factor: 12.300

4.  Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination.

Authors:  M Steklov; S Pandolfi; M F Baietti; A Batiuk; P Carai; P Najm; M Zhang; H Jang; F Renzi; Y Cai; L Abbasi Asbagh; T Pastor; M De Troyer; M Simicek; E Radaelli; H Brems; E Legius; J Tavernier; K Gevaert; F Impens; L Messiaen; R Nussinov; S Heymans; S Eyckerman; A A Sablina
Journal:  Science       Date:  2018-11-15       Impact factor: 47.728

5.  Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas.

Authors:  Hildegard Kehrer-Sawatzki; Lan Kluwe; Reinhard E Friedrich; Anna Summerer; Eleonora Schäfer; Ute Wahlländer; Cordula Matthies; Isabel Gugel; Said Farschtschi; Christian Hagel; David N Cooper; Victor-Felix Mautner
Journal:  Hum Genet       Date:  2018-07-13       Impact factor: 4.132

Review 6.  [Pathogenesis and molecular pathology of vestibular schwannoma].

Authors:  M Brodhun; V Stahn; A Harder
Journal:  HNO       Date:  2017-05       Impact factor: 1.284

7.  Recurrent Schwannomatosis of the Hand.

Authors:  Razvan Nicolescu; Nikhil A Agrawal; Rowland W Pettit; David T Netscher
Journal:  Hand (N Y)       Date:  2020-01-16

8.  Unilateral vestibular schwannoma in a patient with schwannomatosis in the absence of LZTR1 mutation.

Authors:  Gautam U Mehta; Michael J Feldman; Herui Wang; Dale Ding; Prashant Chittiboina
Journal:  J Neurosurg       Date:  2016-02-05       Impact factor: 5.115

9.  Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1-PPP1CB complexes.

Authors:  Ikumi Umeki; Tetsuya Niihori; Taiki Abe; Shin-Ichiro Kanno; Nobuhiko Okamoto; Seiji Mizuno; Kenji Kurosawa; Keisuke Nagasaki; Makoto Yoshida; Hirofumi Ohashi; Shin-Ichi Inoue; Yoichi Matsubara; Ikuma Fujiwara; Shigeo Kure; Yoko Aoki
Journal:  Hum Genet       Date:  2018-10-27       Impact factor: 4.132

10.  Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis.

Authors:  Miriam J Smith; Naomi L Bowers; Michael Bulman; Carolyn Gokhale; Andrew J Wallace; Andrew T King; Simon K L Lloyd; Scott A Rutherford; Charlotte L Hammerbeck-Ward; Simon R Freeman; D Gareth Evans
Journal:  Neurology       Date:  2016-11-16       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.